Kala Pharmaceuticals (NASDAQ:KALA) announced its quarterly earnings results on Thursday. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.01), Fidelity Earnings reports. The firm had revenue of $1.45 million for the quarter, compared to analyst estimates of $3.56 million.
Kala Pharmaceuticals stock traded up $0.40 during trading on Friday, hitting $4.11. The company had a trading volume of 374,000 shares, compared to its average volume of 249,192. The company has a current ratio of 7.50, a quick ratio of 7.04 and a debt-to-equity ratio of 1.16. The stock has a market cap of $126.17 million, a price-to-earnings ratio of -1.66 and a beta of 2.13. Kala Pharmaceuticals has a 1-year low of $3.24 and a 1-year high of $9.25. The company’s 50 day simple moving average is $3.84 and its 200-day simple moving average is $5.11.
Several analysts recently weighed in on the stock. ValuEngine upgraded shares of Kala Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Zacks Investment Research upgraded shares of Kala Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a report on Wednesday. HC Wainwright dropped their target price on shares of Kala Pharmaceuticals from $15.00 to $12.00 and set a “buy” rating for the company in a report on Wednesday, August 7th. JPMorgan Chase & Co. dropped their target price on shares of Kala Pharmaceuticals from $22.00 to $14.00 and set an “overweight” rating for the company in a report on Friday. Finally, Wedbush reiterated an “outperform” rating and issued a $51.00 target price on shares of Kala Pharmaceuticals in a report on Wednesday, August 7th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Kala Pharmaceuticals has a consensus rating of “Buy” and an average price target of $17.54.
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
See Also: Index Funds
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.